Skip to main content
Top
Published in: Pathology & Oncology Research 3/2020

01-07-2020 | Hysterectomy | Review

Diabetes Mellitus Is Associated with Occult Cancer in Endometrial Hyperplasia

Authors: Antonio Raffone, Antonio Travaglino, Gabriele Saccone, Pietro D’Alessandro, Bruno Arduino, Massimo Mascolo, Giuseppe De Placido, Luigi Insabato, Fulvio Zullo

Published in: Pathology & Oncology Research | Issue 3/2020

Login to get access

Abstract

In the management of women diagnosed with endometrial hyperplasia (EH), it is crucial to determine the risk of coexistent cancer. Diabetes mellitus has been recently suggested as a significant risk factor. However, results in this regard are conflicting. Our aim was to assess the association between diabetes mellitus and coexistent cancer in women diagnosed with endometrial hyperplasia. A systematic review and meta-analysis was performed by searching electronic databases from their inception to October 2018 for studies assessing the presence of coexistent cancer after a preoperative diagnosis of endometrial hyperplasia in women stratified for diabetes mellitus. Odds ratio was calculated with 95% confidence interval; a p value <0.05 was considered significant. Twelve retrospective studies with 1579 EH were included. Diabetes mellitus showed significant association with the presence of cancer coexistent with endometrial hyperplasia (OR = 1.96; 95% CI, 1.07–3.60; p = 0.03). Heterogeneity among studies was moderate (I2 = 55%). Funnel plot showed asymmetric distribution of OR values, with the large and accurate studies showing results stronger than small and less accurate one; this finding should exclude a publication bias. In women diagnosed with endometrial hyperplasia, diabetes mellitus is a risk factor for coexistent cancer, and thus may be included in a predictive algorithm for the risk stratification. In women conservatively treated, glycemic control may be required to prevent the risk of progression. Further studies are necessary to confirm the clinical significance of diabetes mellitus in this field.
Literature
1.
go back to reference Kurman R, Carcangiu M, Herrington C, Young R (2014) World Health Organisation classification of tumors of female reproductive organs, 4th edn. International Agency for Research on Cancer (IARC) Press, Lyon Kurman R, Carcangiu M, Herrington C, Young R (2014) World Health Organisation classification of tumors of female reproductive organs, 4th edn. International Agency for Research on Cancer (IARC) Press, Lyon
2.
go back to reference Sanderson PA, Critchley HOD, Williams ARW, Arends MJ, Saunders PTK (2017) New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update 23(2):232–254PubMed Sanderson PA, Critchley HOD, Williams ARW, Arends MJ, Saunders PTK (2017) New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update 23(2):232–254PubMed
3.
go back to reference Travaglino A, Raffone A, Saccone G et al (2018) Endometrial hyperplasia and risk of coexistent cancer: WHO vs EIN criteria. Histopathology. Travaglino A, Raffone A, Saccone G et al (2018) Endometrial hyperplasia and risk of coexistent cancer: WHO vs EIN criteria. Histopathology.
5.
go back to reference Ordi J, Bergeron C, Hardisson D, McCluggage WG, Hollema H, Felix A, Soslow RA, Oliva E, Tavassoli FA, Alvarado-Cabrero I, Wells M, Nogales FF (2014) Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. Histopathology. 64(2):284–292PubMedCrossRef Ordi J, Bergeron C, Hardisson D, McCluggage WG, Hollema H, Felix A, Soslow RA, Oliva E, Tavassoli FA, Alvarado-Cabrero I, Wells M, Nogales FF (2014) Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. Histopathology. 64(2):284–292PubMedCrossRef
7.
go back to reference Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, de Placido G, Zullo F (2018) Loss of Bcl-2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment. A systematic review and meta-analysis. Acta Obstet Gynecol Scand 97:1415–1426PubMedCrossRef Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, de Placido G, Zullo F (2018) Loss of Bcl-2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment. A systematic review and meta-analysis. Acta Obstet Gynecol Scand 97:1415–1426PubMedCrossRef
8.
go back to reference Raffone A, Travaglino A, Saccone G, Mascolo M, Insabato L, Mollo A, de Placido G, Zullo F (2019) PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia. A systematic review and meta-analysis of diagnostic accuracy. Acta Obstet Gynecol Scand 98(3):287–299CrossRefPubMed Raffone A, Travaglino A, Saccone G, Mascolo M, Insabato L, Mollo A, de Placido G, Zullo F (2019) PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia. A systematic review and meta-analysis of diagnostic accuracy. Acta Obstet Gynecol Scand 98(3):287–299CrossRefPubMed
9.
go back to reference Raffone A, Travaglino A, Saccone G, Campanino MR, Mollo A, de Placido G, Insabato L, Zullo F (2019) Loss of PTEN expression as diagnostic marker of endometrial precancer: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 98(3):275–286PubMedCrossRef Raffone A, Travaglino A, Saccone G, Campanino MR, Mollo A, de Placido G, Insabato L, Zullo F (2019) Loss of PTEN expression as diagnostic marker of endometrial precancer: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 98(3):275–286PubMedCrossRef
11.
go back to reference Chen YL, Cheng WF, Lin MC, Huang CY, Hsieh CY, Chen CA (2009) Concurrent endometrial carcinoma in patients with a curettage diagnosis of endometrial hyperplasia. J Formos Med Assoc 108(6):502–507PubMedCrossRef Chen YL, Cheng WF, Lin MC, Huang CY, Hsieh CY, Chen CA (2009) Concurrent endometrial carcinoma in patients with a curettage diagnosis of endometrial hyperplasia. J Formos Med Assoc 108(6):502–507PubMedCrossRef
12.
go back to reference Chen YL, Wang KL, Chen MY, Yu MH, Wu CH, Ke YM, Chen YJ, Chang YY, Hsu KF, Yen MS (2013) Risk factor analysis of coexisting endometrial carcinoma in patients with endometrial hyperplasia: a retrospective observational study of Taiwanese gynecologic oncology group. J Gynecol Oncol 24(1):14–20PubMedPubMedCentralCrossRef Chen YL, Wang KL, Chen MY, Yu MH, Wu CH, Ke YM, Chen YJ, Chang YY, Hsu KF, Yen MS (2013) Risk factor analysis of coexisting endometrial carcinoma in patients with endometrial hyperplasia: a retrospective observational study of Taiwanese gynecologic oncology group. J Gynecol Oncol 24(1):14–20PubMedPubMedCentralCrossRef
13.
go back to reference Matsuo K, Ramzan AA, Gualtieri MR, Mhawech-Fauceglia P, Machida H, Moeini A, Dancz CE, Ueda Y, Roman LD (2015) Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. Gynecol Oncol 139(2):261–267PubMedCrossRefPubMedCentral Matsuo K, Ramzan AA, Gualtieri MR, Mhawech-Fauceglia P, Machida H, Moeini A, Dancz CE, Ueda Y, Roman LD (2015) Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. Gynecol Oncol 139(2):261–267PubMedCrossRefPubMedCentral
14.
go back to reference Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1) Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1)
15.
go back to reference Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, QUADAS-2 Group (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536CrossRefPubMed Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, QUADAS-2 Group (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536CrossRefPubMed
16.
go back to reference Lacey JV Jr, Mutter GL, Nucci MR, Ronnett BM, Ioffe OB, Rush BB, Glass AG, Richesson DA, Chatterjee N, Langholz B, Sherman ME (2008) Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 113(8):2073–2081PubMedCrossRef Lacey JV Jr, Mutter GL, Nucci MR, Ronnett BM, Ioffe OB, Rush BB, Glass AG, Richesson DA, Chatterjee N, Langholz B, Sherman ME (2008) Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer 113(8):2073–2081PubMedCrossRef
17.
go back to reference Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Ørbo A, Palazzo J, Fiane B, Løvslett K, Burger C, Voorhorst F, Verheijen RH (2005) The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer. 103(11):2304–2312PubMedCrossRef Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Ørbo A, Palazzo J, Fiane B, Løvslett K, Burger C, Voorhorst F, Verheijen RH (2005) The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer. 103(11):2304–2312PubMedCrossRef
18.
go back to reference Menke A, Casagrande S, Geiss L, Cowie CC (2015) Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 314(10):1021–1029PubMedCrossRef Menke A, Casagrande S, Geiss L, Cowie CC (2015) Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 314(10):1021–1029PubMedCrossRef
19.
go back to reference Widra EA, Dunton CJ, McHugh M, Palazzo JP (1995 May) Endometrial hyperplasia and the risk of carcinoma. Int J Gynecol Cancer 5(3):233–235PubMedCrossRef Widra EA, Dunton CJ, McHugh M, Palazzo JP (1995 May) Endometrial hyperplasia and the risk of carcinoma. Int J Gynecol Cancer 5(3):233–235PubMedCrossRef
20.
go back to reference Bilgin T, Ozuysal S, Ozan H, Atakan T (2004) Coexisting endometrial cancer in patients with a preoperative diagnosis of atypical endometrial hyperplasia. J Obstet Gynaecol Res 30(3):205–209PubMedCrossRef Bilgin T, Ozuysal S, Ozan H, Atakan T (2004) Coexisting endometrial cancer in patients with a preoperative diagnosis of atypical endometrial hyperplasia. J Obstet Gynaecol Res 30(3):205–209PubMedCrossRef
21.
go back to reference Merisio C, Berretta R, De Ioris A et al (2005) Endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 122(1):107–111PubMedCrossRef Merisio C, Berretta R, De Ioris A et al (2005) Endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 122(1):107–111PubMedCrossRef
22.
go back to reference Daud S, Jalil SS, Griffin M, Ewies AA (2011 Nov) Endometrial hyperplasia - the dilemma of management remains: a retrospective observational study of 280 women. Eur J Obstet Gynecol Reprod Biol 159(1):172–175PubMedCrossRef Daud S, Jalil SS, Griffin M, Ewies AA (2011 Nov) Endometrial hyperplasia - the dilemma of management remains: a retrospective observational study of 280 women. Eur J Obstet Gynecol Reprod Biol 159(1):172–175PubMedCrossRef
23.
go back to reference Robbe EJ, van Kuijk SM, de Boed EM et al (2012) Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: immunohistochemical analysis of endometrial samples. Int J Gynecol Cancer 22(7):1264–1272PubMedCrossRef Robbe EJ, van Kuijk SM, de Boed EM et al (2012) Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: immunohistochemical analysis of endometrial samples. Int J Gynecol Cancer 22(7):1264–1272PubMedCrossRef
24.
go back to reference Touboul C, Piel B, Koskas M, Gonthier C, Ballester M, Cortez A, Daraï E (2014) Factors predictive of endometrial carcinoma in patients with atypical endometrial hyperplasia on preoperative histology. Anticancer Res 34(10):5671–5676PubMed Touboul C, Piel B, Koskas M, Gonthier C, Ballester M, Cortez A, Daraï E (2014) Factors predictive of endometrial carcinoma in patients with atypical endometrial hyperplasia on preoperative histology. Anticancer Res 34(10):5671–5676PubMed
25.
go back to reference Zhou L, Meng Z, Wu Y, Zhu H, Wang X (2014) Prediction of endometrial carcinogenesis probability while diagnosed as atypical endometrial hyperplasia: a new risk model based on age, CA199 and CA125 assay. Eur J Obstet Gynecol Reprod Biol 183:5–9PubMedCrossRef Zhou L, Meng Z, Wu Y, Zhu H, Wang X (2014) Prediction of endometrial carcinogenesis probability while diagnosed as atypical endometrial hyperplasia: a new risk model based on age, CA199 and CA125 assay. Eur J Obstet Gynecol Reprod Biol 183:5–9PubMedCrossRef
26.
go back to reference Dolanbay M, Kutuk MS, Uludag S, Bulut A, Ozgun M, Ozcelik B, Serin I (2015) Concurrent endometrial carcinoma in hysterectomy specimens in patients with histopathological diagnosis of endometrial hyperplasia in curettage specimens. Ginekol Pol 86(10):753–758PubMedCrossRef Dolanbay M, Kutuk MS, Uludag S, Bulut A, Ozgun M, Ozcelik B, Serin I (2015) Concurrent endometrial carcinoma in hysterectomy specimens in patients with histopathological diagnosis of endometrial hyperplasia in curettage specimens. Ginekol Pol 86(10):753–758PubMedCrossRef
27.
go back to reference Kadirogullari P, Atalay CR, Ozdemir O, Sari ME (2015) Prevalence of co-existing endometrial carcinoma in patients with preoperative diagnosis of endometrial hyperplasia. J Clin Diagn Res 9(10):QC10–QC14PubMedPubMedCentral Kadirogullari P, Atalay CR, Ozdemir O, Sari ME (2015) Prevalence of co-existing endometrial carcinoma in patients with preoperative diagnosis of endometrial hyperplasia. J Clin Diagn Res 9(10):QC10–QC14PubMedPubMedCentral
28.
go back to reference Ferenczy A, Gelfand MM, Tzipris F (1983) The cytodynamics of endometrial hyperplasia and carcinoma. A review. Ann Pathol 3(3):189–201PubMed Ferenczy A, Gelfand MM, Tzipris F (1983) The cytodynamics of endometrial hyperplasia and carcinoma. A review. Ann Pathol 3(3):189–201PubMed
32.
go back to reference Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, Gabra H, Paraskevaidis E, Martin-Hirsch P, Tsilidis KK, Kyrgiou M (2018) Risk factors for endometrial Cancer: an umbrella review of the literature. Int J Cancer. https://doi.org/10.1002/ijc.31961 Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, Gabra H, Paraskevaidis E, Martin-Hirsch P, Tsilidis KK, Kyrgiou M (2018) Risk factors for endometrial Cancer: an umbrella review of the literature. Int J Cancer. https://​doi.​org/​10.​1002/​ijc.​31961
33.
go back to reference Fader AN, Arriba LN, Frasure HE, von Gruenigen VE (2009) Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 114(1):121–127PubMedCrossRef Fader AN, Arriba LN, Frasure HE, von Gruenigen VE (2009) Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 114(1):121–127PubMedCrossRef
34.
go back to reference Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928PubMedCrossRef Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915–928PubMedCrossRef
35.
go back to reference Sasaki LMP, Andrade KRC, Figueiredo ACMG, Wanderley MDS, Pereira MG (2018) Factors associated with malignancy in Hysteroscopically resected endometrial polyps: a systematic review and meta-analysis. J Minim Invasive Gynecol 25(5):777–785PubMedCrossRef Sasaki LMP, Andrade KRC, Figueiredo ACMG, Wanderley MDS, Pereira MG (2018) Factors associated with malignancy in Hysteroscopically resected endometrial polyps: a systematic review and meta-analysis. J Minim Invasive Gynecol 25(5):777–785PubMedCrossRef
36.
go back to reference Management of Endometrial Hyperplasia Green-top Guideline No. 67 RCOG/BSGE joint guideline | February 2016 Management of Endometrial Hyperplasia Green-top Guideline No. 67 RCOG/BSGE joint guideline | February 2016
37.
go back to reference Zhang Q, Qi G, Kanis MJ, Dong R, Cui B, Yang X, Kong B (2017 May 3) Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia. Oncotarget. 8(34):57642–57653PubMedPubMedCentralCrossRef Zhang Q, Qi G, Kanis MJ, Dong R, Cui B, Yang X, Kong B (2017 May 3) Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia. Oncotarget. 8(34):57642–57653PubMedPubMedCentralCrossRef
38.
go back to reference Giampaolino P, Di Spiezio Sardo A, Mollo A et al (2018) Hysteroscopic endometrial focal resection followed by Levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial Cancer: a retrospective study. J Minim Invasive Gynecol Giampaolino P, Di Spiezio Sardo A, Mollo A et al (2018) Hysteroscopic endometrial focal resection followed by Levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial Cancer: a retrospective study. J Minim Invasive Gynecol
39.
go back to reference Raffone A, Travaglino A, Saccone G, Alviggi C, Mascolo M, de Placido G, Insabato L, Mollo A, Zullo F (2019) Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review. Acta Obstet Gynecol Scand. https://doi.org/10.1111/aogs.13553 Raffone A, Travaglino A, Saccone G, Alviggi C, Mascolo M, de Placido G, Insabato L, Mollo A, Zullo F (2019) Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review. Acta Obstet Gynecol Scand. https://​doi.​org/​10.​1111/​aogs.​13553
40.
go back to reference Meireles CG, Pereira SA, Valadares LP, Rêgo DF, Simeoni LA, Guerra ENS, Lofrano-Porto A (2017) Effects of metformin on endometrial cancer: systematic review and meta-analysis. Gynecol Oncol 147(1):167–180PubMedCrossRef Meireles CG, Pereira SA, Valadares LP, Rêgo DF, Simeoni LA, Guerra ENS, Lofrano-Porto A (2017) Effects of metformin on endometrial cancer: systematic review and meta-analysis. Gynecol Oncol 147(1):167–180PubMedCrossRef
41.
go back to reference Raffone A, Travaglino A, Saccone G, Mollo A, de Placido G, Insabato L, Zullo F (2019) Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand. https://doi.org/10.1111/aogs.13586 Raffone A, Travaglino A, Saccone G, Mollo A, de Placido G, Insabato L, Zullo F (2019) Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand. https://​doi.​org/​10.​1111/​aogs.​13586
42.
go back to reference Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, de Placido G, Zullo F (2018) PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 231:104–110PubMedCrossRef Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, de Placido G, Zullo F (2018) PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 231:104–110PubMedCrossRef
43.
go back to reference Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, de Placido G, Zullo F (2019) Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. https://doi.org/10.1111/aogs.13587 Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, de Placido G, Zullo F (2019) Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. https://​doi.​org/​10.​1111/​aogs.​13587
44.
go back to reference Raffone A, Travaglino A, Saccone G, Di Maio A, Mollo A, Mascolo M, De Rosa R, De Placido G, Insabato L, Zullo F, (2019) Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecological Endocrinology:1-6 Raffone A, Travaglino A, Saccone G, Di Maio A, Mollo A, Mascolo M, De Rosa R, De Placido G, Insabato L, Zullo F, (2019) Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecological Endocrinology:1-6
Metadata
Title
Diabetes Mellitus Is Associated with Occult Cancer in Endometrial Hyperplasia
Authors
Antonio Raffone
Antonio Travaglino
Gabriele Saccone
Pietro D’Alessandro
Bruno Arduino
Massimo Mascolo
Giuseppe De Placido
Luigi Insabato
Fulvio Zullo
Publication date
01-07-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00684-3

Other articles of this Issue 3/2020

Pathology & Oncology Research 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine